TriangleNCT03493451 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 3 years and 1 week
What was measured
OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.
Analysis population: Safety analysis set includes all participants who received at least one dose of study drug
Groups in this outcome
Cohort 1: ENKTL
Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
Cohort 2: PTCL-NOS, AITL, and ALCL
Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
| Group | Source count |
|---|---|
| Cohort 1: ENKTL | 22 |
| Cohort 2: PTCL-NOS, AITL, and ALCL | 44 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort 1: ENKTL | 8.8 | Not reported | 3.25 | NA | Upper limit of confidence interval not estimable due to insufficient number of participants with events |
| Cohort 2: PTCL-NOS, AITL, and ALCL | 13.3 | Not reported | 7.66 | 26.22 | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Upper limit of confidence interval not estimable due to insufficient number of participants with events
- group Id
- OG000
- lower Limit
- 3.25
- upper Limit
- NA
- value
- 8.8
- group Id
- OG001
- lower Limit
- 7.66
- upper Limit
- 26.22
- value
- 13.3
- denoms
- counts
- group Id
- OG000
- value
- 22
- group Id
- OG001
- value
- 44
- units
- Participants
- description
- OS defined as the time from first study drug administration to the date of death due to any reason for cohorts 1 and 2.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- OG000
- title
- Cohort 1: ENKTL
- description
- Participants with other R/R mature T-cell neoplasms \[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)
- id
- OG001
- title
- Cohort 2: PTCL-NOS, AITL, and ALCL
- param Type
- MEDIAN
- population Description
- Safety analysis set includes all participants who received at least one dose of study drug
- reporting Status
- POSTED
- time Frame
- Up to approximately 3 years and 1 week
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice